384 related articles for article (PubMed ID: 16406966)
1. Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
3. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
4. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
5. TRAIL and apoptosis induction by TNF-family death receptors.
Wang S; El-Deiry WS
Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
[TBL] [Abstract][Full Text] [Related]
6. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
Schimmer AD; Thomas MP; Hurren R; Gronda M; Pellecchia M; Pond GR; Konopleva M; Gurfinkel D; Mawji IA; Brown E; Reed JC
Cancer Res; 2006 Feb; 66(4):2367-75. PubMed ID: 16489043
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
8. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
9. [Death inducing ligands in combination with ionizing radiation: objective and current knowledge].
Belka C; Betsch A; Marini P; Jendrossek V; Bamberg M; Budach W
Strahlenther Onkol; 2003 Mar; 179(3):141-51. PubMed ID: 12627256
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications.
Shankar S; Srivastava RK
Drug Resist Updat; 2004 Apr; 7(2):139-56. PubMed ID: 15158769
[TBL] [Abstract][Full Text] [Related]
12. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor and trail interactions in epithelial-derived cells.
Gibson SB
Vitam Horm; 2004; 67():207-27. PubMed ID: 15110179
[TBL] [Abstract][Full Text] [Related]
14. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
El-Deiry WS
Cell Death Differ; 2001 Nov; 8(11):1066-75. PubMed ID: 11687885
[TBL] [Abstract][Full Text] [Related]
15. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
Mori E; Thomas M; Motoki K; Kataika S
FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145.
Yun JM; Kweon MH; Kwon H; Hwang JK; Mukhtar H
Carcinogenesis; 2006 Jul; 27(7):1454-64. PubMed ID: 16497706
[TBL] [Abstract][Full Text] [Related]
17. cIAP-2 block apoptotic events in bladder cancer cells.
Jönsson G; Paulie S; Grandien A
Anticancer Res; 2003; 23(4):3311-6. PubMed ID: 12926068
[TBL] [Abstract][Full Text] [Related]
18. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
Younes A; Kadin ME
J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
[TBL] [Abstract][Full Text] [Related]
19. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Thorpe JA; Christian PA; Schwarze SR
Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
